{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:02:27Z","timestamp":1746417747860,"version":"3.40.4"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"31","license":[{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>At present, the prognosis of patients with giant lung squamous cell carcinoma (LSCC) is poor, and there is no safe and effective treatment for elderly patients with large LSCC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>Here, we reported a 77-year-old man admitted to the hospital with cough for 3 months and significant chest pain. Computed tomography (CT) imaging showed a large mass in the left lung with pleural effusion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Chest CT scan revealed a 12.5\u200acm\u200a\u00d7\u200a7.3\u200acm mass in the left upper lobe adjacent to the pulmonary vein, with left pleural effusion. Pulmonary tumor markers were significantly elevated, and CT-guided percutaneous lung mass biopsy specimens showed LSCC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>After diagnosis, the patient was treated with sintilimab combined with endostar and nab-paclitaxel. After 2 cycles of treatment, the lung mass in the patient shrank rapidly and the clinical symptoms were relieved.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient's tumor dramatically shrank, and the pleural effusion was decreased after 4 cycles of treatment without any adverse effects. Meanwhile, the high-level tumor marker resumed normal.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Sintilimab combined with endostar and nab-paclitaxel may be a good treatment option for lung squamous cell cancer, especially for that in elderly patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026801","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T19:41:03Z","timestamp":1629142863000},"page":"e26801","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["A rapid response of lung squamous cell carcinoma following treatment with sintilimab combined with recombinant humane endostatin injection and nab-paclitaxel in an elderly patient"],"prefix":"10.1097","volume":"100","author":[{"given":"Yueyu","family":"Fang","sequence":"first","affiliation":[{"name":"Department of Oncology, Nanjing Pukou Central Hospital, Pukou Branch Hospital of Jiangsu Province Hospital, Nanjing, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Pukou Central Hospital, Pukou Branch Hospital of Jiangsu Province Hospital, Nanjing, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Pukou Central Hospital, Pukou Branch Hospital of Jiangsu Province Hospital, Nanjing, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanyuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Pukou Central Hospital, Pukou Branch Hospital of Jiangsu Province Hospital, Nanjing, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianhua","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Pukou Central Hospital, Pukou Branch Hospital of Jiangsu Province Hospital, Nanjing, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6424-3149","authenticated-orcid":false,"given":"Junfeng","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, People's Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,8,6]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jtho.2017.11.111","article-title":"Current and emergent therapy options for advanced squamous cell lung cancer","volume":"13","author":"Socinski","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1158\/1078-0432.CCR-17-3620","article-title":"The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer","volume":"24","author":"Ko","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","article-title":"Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1\u201311)","volume":"15","author":"Yang","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.bbagen.2015.09.007","article-title":"Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications","volume":"1850","author":"Walia","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"298","DOI":"10.21037\/apm.2020.01.16","article-title":"Endostar improved efficacy of concurrent chemoradiotherapy with vinorelbine plus carboplatin in locally advanced lung squamous cell carcinoma patients with high serum Lp(a) concentration","volume":"9","author":"Xu","year":"2020","journal-title":"Ann Palliat Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"e11822","DOI":"10.1097\/MD.0000000000011822","article-title":"Influence of different drug delivery methods for Endostar combined with a gemcitabine\/cisplatin regimen in locally advanced or metastatic lung squamous cell carcinoma: a retrospective observational study","volume":"97","author":"Yao","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R9-20250504","first-page":"670","article-title":"Recombinant human endostatin in the treatment of advanced lung squamous cell carcinoma","volume":"19","author":"Xing","year":"2016","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.radonc.2018.10.032","article-title":"HELPER study: a phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer","volume":"131","author":"Zhai","year":"2019","journal-title":"Radiother Oncol"},{"key":"R11-20250504","first-page":"287","article-title":"Recent advances in non-small cell lung cancer biology and clinical management","volume":"13","author":"Saintigny","year":"2012","journal-title":"Discov Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2014.59.4424","article-title":"BEYOND: a randomized, double-blind, placebo-controlled, multicenter, Phase III study of first-line carboplatin\/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer","volume":"33","author":"Zhou","year":"2015","journal-title":"J Clin Oncol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"E822","DOI":"10.1002\/ijc.27396","article-title":"Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials","volume":"131","author":"Gao","year":"2012","journal-title":"Int J Cancer"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"issue":"(suppl)","key":"R15-20250504","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.6004\/jnccn.2014.0176","article-title":"Non-small cell lung cancer, version 1.2015","volume":"12","author":"Ettinger","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.2147\/OTT.S104177","article-title":"New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib","volume":"10","author":"Hirsh","year":"2017","journal-title":"Onco Targets Ther"},{"issue":"(suppl)","key":"R18-20250504","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.3747\/co.25.3792","article-title":"Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview","volume":"25","author":"Daaboul","year":"2018","journal-title":"Curr Oncol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"102731","DOI":"10.1016\/j.ebiom.2020.102731","article-title":"Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab","volume":"54","author":"Shi","year":"2020","journal-title":"EBioMedicine"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1080\/19420862.2019.1654303","article-title":"Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit","volume":"11","author":"Wang","year":"2019","journal-title":"MAbs"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"594558","DOI":"10.3389\/fonc.2020.594558","article-title":"Sintilimab: a promising anti-tumor PD-1 antibody","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jtho.2020.01.017","article-title":"Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC","volume":"15","author":"Gao","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1056\/NEJMx180040","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer; nivolumab and ipilimumab in advanced melanoma; overall survival with combined nivolumab and ipilimumab in advanced melanoma; prolonged survival in stage III melanoma with ipilimumab adjuvant therapy; combined nivolumab and ipilimumab or monotherapy in untreated melanoma; combined nivolumab and ipilimumab or monotherapy in untreated melanoma; nivolumab and ipilimumab versus ipilimumab in untreated melanoma; rapid eradication of a bulky melanoma mass with one dose of immunotherapy; genetic basis for clinical response to CTLA-4 blockade; genetic basis for clinical response to ctla-4 blockade in melanoma; nivolumab plus ipilimumab in advanced melanoma; safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma; hepatotoxicity with combination of vemurafenib and ipilimumab","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00262-020-02738-x","article-title":"Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study","volume":"70","author":"Jiang","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"(suppl)","key":"R27-20250504","doi-asserted-by":"crossref","first-page":"S1428","DOI":"10.1016\/j.annonc.2020.10.517","article-title":"RETRACTED: ORIENT-3: a randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced\/metastatic squamous non-small cell lung cancer (sqNSCLC)","volume":"31","author":"Shi","year":"2020","journal-title":"Ann Oncol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"e19790","DOI":"10.1097\/MD.0000000000019790","article-title":"Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer: A case report","volume":"99","author":"Zhang","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"(6 suppl 16)","key":"R29-20250504","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/sonc.2002.37263","article-title":"Role of angiogenesis in tumor growth and metastasis","volume":"29","author":"Folkman","year":"2002","journal-title":"Semin Oncol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bone.2013.07.035","article-title":"Effects of endostar combined multidrug chemotherapy in osteosarcoma","volume":"57","author":"Xu","year":"2013","journal-title":"Bone"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/147323001003800113","article-title":"The synergistic effect of recombinant human endostatin (YH-16) combined with oxaliplatin on human colorectal carcinoma","volume":"38","author":"Zhang","year":"2010","journal-title":"J Int Med Res"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"33926","DOI":"10.18632\/oncotarget.5271","article-title":"The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma","volume":"6","author":"Guan","year":"2015","journal-title":"Oncotarget"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/1759-7714.12050","article-title":"Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer","volume":"4","author":"Sun","year":"2013","journal-title":"Thorac Cancer"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1477-7819-10-170","article-title":"Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer","volume":"10","author":"Rong","year":"2012","journal-title":"World J Surg Oncol"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1186\/s12885-020-07527-4","article-title":"Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Cancer"},{"issue":"(pt 2)","key":"R36-20250504","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.semcancer.2018.06.002","article-title":"The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer","volume":"52","author":"Missiaen","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(19)30458-9","article-title":"Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a\/b trial","volume":"20","author":"Herbst","year":"2019","journal-title":"Lancet Oncol"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jtho.2020.11.026","article-title":"Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC","volume":"16","author":"Chu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-017-0521-0","article-title":"Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study","volume":"10","author":"Liu","year":"2017","journal-title":"J Hematol Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:41:36Z","timestamp":1746337296000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026801"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,8,6]]},"references-count":40,"journal-issue":{"issue":"31","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026801","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,8,6]]},"assertion":[{"value":"2021-04-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}